{"id":"NCT02021318","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","officialTitle":"A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-12","primaryCompletion":"2018-03-23","completion":"2019-11-06","firstPosted":"2013-12-27","resultsPosted":"2021-03-29","lastUpdate":"2024-11-14"},"enrollment":616,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia in Chronic Kidney Disease in Non-dialysis Patients"],"interventions":[{"type":"DRUG","name":"Roxadustat","otherNames":["ASP1517"]},{"type":"DRUG","name":"Darbepoetin alfa","otherNames":["Aranesp"]}],"arms":[{"label":"Roxadustat","type":"EXPERIMENTAL"},{"label":"Darbepoetin alfa","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.","primaryOutcome":{"measure":"Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"Roxadustat","deltaMin":89.5,"sd":null},{"arm":"Darbepoetin Alfa","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":24},"locations":{"siteCount":125,"countries":["Austria","Belarus","Bulgaria","Croatia","Czechia","Finland","France","Georgia","Germany","Hungary","Ireland","Israel","Latvia","Montenegro","Netherlands","North Macedonia","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["36749544","36005278"],"seeAlso":["https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=401"]},"adverseEventsSummary":{"seriousAny":{"events":209,"n":323},"commonTop":["Hypertension","Oedema peripheral","Hyperkalaemia","Glomerular filtration rate decreased","Nausea"]}}